These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26964739)

  • 1. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models.
    Koussounadis A; Langdon SP; Um I; Kay C; Francis KE; Harrison DJ; Smith VA
    BMC Cancer; 2016 Mar; 16():205. PubMed ID: 26964739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy-induced dynamic gene expression changes in vivo are prognostic in ovarian cancer.
    Koussounadis A; Langdon SP; Harrison DJ; Smith VA
    Br J Cancer; 2014 Jun; 110(12):2975-84. PubMed ID: 24867692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail‑glycolysis pathways.
    Jia L; Zhou J; Zhao H; Jin H; Lv M; Zhao N; Zheng Z; Lu Y; Ming Y; Yu Y
    Oncol Rep; 2017 Oct; 38(4):2464-2470. PubMed ID: 28791374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
    Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KDM1A/LSD1 inhibition enhances chemotherapy response in ovarian cancer.
    Chen Y; Johnson JD; Jayamohan S; He Y; Venkata PP; Jamwal D; Alejo S; Zou Y; Lai Z; Viswanadhapalli S; Vadlamudi RK; Kost E; Sareddy GR
    Mol Carcinog; 2024 Oct; 63(10):2026-2039. PubMed ID: 38990091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer.
    Huang R; Langdon SP; Tse M; Mullen P; Um IH; Faratian D; Harrison DJ
    Oncotarget; 2016 Jan; 7(4):4695-711. PubMed ID: 26683361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
    Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
    Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.
    Shu T; Li Y; Wu X; Li B; Liu Z
    Cancer Lett; 2017 Dec; 411():65-73. PubMed ID: 28989055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
    Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
    Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
    Bradford LS; Rauh-Hain A; Clark RM; Groeneweg JW; Zhang L; Borger D; Zukerberg LR; Growdon WB; Foster R; Rueda BR
    Gynecol Oncol; 2014 May; 133(2):346-52. PubMed ID: 24561032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.
    Glaser G; Weroha SJ; Becker MA; Hou X; Enderica-Gonzalez S; Harrington SC; Haluska P
    PLoS One; 2015; 10(5):e0126867. PubMed ID: 25962155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.
    Beltran PJ; Calzone FJ; Mitchell P; Chung YA; Cajulis E; Moody G; Belmontes B; Li CM; Vonderfecht S; Velculescu VE; Yang G; Qi J; Slamon DJ; Konecny GE
    Clin Cancer Res; 2014 Jun; 20(11):2947-58. PubMed ID: 24727326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer.
    Liu J; Agopiantz M; Poupon J; Wu Z; Just PA; Borghese B; Ségal-Bendirdjian E; Gauchotte G; Gompel A; Forgez P
    Clin Cancer Res; 2017 Nov; 23(21):6516-6528. PubMed ID: 28790113
    [No Abstract]   [Full Text] [Related]  

  • 15. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
    Thibault B; Jean-Claude B
    J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.
    Faratian D; Zweemer AJ; Nagumo Y; Sims AH; Muir M; Dodds M; Mullen P; Um I; Kay C; Hasmann M; Harrison DJ; Langdon SP
    Clin Cancer Res; 2011 Jul; 17(13):4451-61. PubMed ID: 21571868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platinum-based chemotherapy and bevacizumab instigate the destruction of human ovarian cancers via different signaling pathways.
    Kingnate C; Charoenkwan K; Kumfu S; Apaijai N; Jaiwongkam T; Khunamornpong S; Chattipakorn N; Chattipakorn SC
    Biochem Pharmacol; 2021 Jun; 188():114587. PubMed ID: 33932471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells.
    Schlosshauer PW; Li W; Lin KT; Chan JL; Wang LH
    Gynecol Oncol; 2009 Sep; 114(3):516-22. PubMed ID: 19576622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer.
    Huang S; Wang D; Zhang S; Huang X; Wang D; Ijaz M; Shi Y
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):685-696. PubMed ID: 28779263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
    Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
    Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.